394 related articles for article (PubMed ID: 22110478)
21. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease.
Sookoian S; Pirola CJ
PLoS One; 2013; 8(3):e58895. PubMed ID: 23516571
[TBL] [Abstract][Full Text] [Related]
22. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk?
Montecucco F; Mach F
Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):301-7. PubMed ID: 19075784
[TBL] [Abstract][Full Text] [Related]
23. Interrelationships between hepatic fat and insulin resistance in non-alcoholic fatty liver disease.
Lockman KA; Nyirenda MJ
Curr Diabetes Rev; 2010 Sep; 6(5):341-7. PubMed ID: 20701585
[TBL] [Abstract][Full Text] [Related]
24. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.
Marchesini G; Brizi M; Bianchi G; Tomassetti S; Bugianesi E; Lenzi M; McCullough AJ; Natale S; Forlani G; Melchionda N
Diabetes; 2001 Aug; 50(8):1844-50. PubMed ID: 11473047
[TBL] [Abstract][Full Text] [Related]
25. [Metabolic fatty liver diseases: hepatic consequences of the metabolic syndrome].
Anty R; Gual P; Huet PM; Marchand-Brustel YL; Tran A
Gastroenterol Clin Biol; 2007 Dec; 31(12):1127-34. PubMed ID: 18176372
[TBL] [Abstract][Full Text] [Related]
26. The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver.
Hörbelt T; Knebel B; Fahlbusch P; Barbosa D; de Wiza DH; Van de Velde F; Van Nieuwenhove Y; Lapauw B; Thoresen GH; Al-Hasani H; Müller-Wieland D; Ouwens DM; Kotzka J
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2671-2684. PubMed ID: 31336149
[TBL] [Abstract][Full Text] [Related]
27. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.
Benhamed F; Denechaud PD; Lemoine M; Robichon C; Moldes M; Bertrand-Michel J; Ratziu V; Serfaty L; Housset C; Capeau J; Girard J; Guillou H; Postic C
J Clin Invest; 2012 Jun; 122(6):2176-94. PubMed ID: 22546860
[TBL] [Abstract][Full Text] [Related]
28. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.
Lomonaco R; Ortiz-Lopez C; Orsak B; Webb A; Hardies J; Darland C; Finch J; Gastaldelli A; Harrison S; Tio F; Cusi K
Hepatology; 2012 May; 55(5):1389-97. PubMed ID: 22183689
[TBL] [Abstract][Full Text] [Related]
29. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
Schuppan D; Schattenberg JM
J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
[TBL] [Abstract][Full Text] [Related]
30. Non-alcoholic fatty liver disease pathogenesis: the present and the future.
Petta S; Muratore C; Craxì A
Dig Liver Dis; 2009 Sep; 41(9):615-25. PubMed ID: 19223251
[TBL] [Abstract][Full Text] [Related]
31. Fatty liver: a novel component of the metabolic syndrome.
Kotronen A; Yki-Järvinen H
Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):27-38. PubMed ID: 17690317
[TBL] [Abstract][Full Text] [Related]
32. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
[TBL] [Abstract][Full Text] [Related]
33. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes.
Lewis GF; Carpentier A; Adeli K; Giacca A
Endocr Rev; 2002 Apr; 23(2):201-29. PubMed ID: 11943743
[TBL] [Abstract][Full Text] [Related]
34. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease.
Qureshi K; Abrams GA
World J Gastroenterol; 2007 Jul; 13(26):3540-53. PubMed ID: 17659704
[TBL] [Abstract][Full Text] [Related]
35. Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARγ.
Floyd ZE; Stephens JM
Biochim Biophys Acta; 2012 Jul; 1822(7):1090-5. PubMed ID: 22504298
[TBL] [Abstract][Full Text] [Related]
36. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
Larter CZ; Chitturi S; Heydet D; Farrell GC
J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
[TBL] [Abstract][Full Text] [Related]
37. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver.
Boden G
Curr Diab Rep; 2006 Jun; 6(3):177-81. PubMed ID: 16898568
[TBL] [Abstract][Full Text] [Related]
38. Retinol-binding protein 4 and new adipocytokines in nonalcoholic fatty liver disease.
Tönjes A; Blüher M; Stumvoll M
Curr Pharm Des; 2010 Jun; 16(17):1921-8. PubMed ID: 20370670
[TBL] [Abstract][Full Text] [Related]
39. Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.
Bechmann LP; Gastaldelli A; Vetter D; Patman GL; Pascoe L; Hannivoort RA; Lee UE; Fiel I; Muñoz U; Ciociaro D; Lee YM; Buzzigoli E; Miele L; Hui KY; Bugianesi E; Burt AD; Day CP; Mari A; Agius L; Walker M; Friedman SL; Reeves HL
Hepatology; 2012 Apr; 55(4):1083-93. PubMed ID: 22095588
[TBL] [Abstract][Full Text] [Related]
40. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.
Polyzos SA; Kountouras J; Zavos C
Curr Mol Med; 2009 Apr; 9(3):299-314. PubMed ID: 19355912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
